Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05088798
Other study ID # 201801029
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date September 10, 2020
Est. completion date January 1, 2030

Study information

Verified date July 2023
Source Washington University School of Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to provide access to 18F-DOPA PET to patients at Washington University and assess the utility of 18F-DOPA PET/MRI as a preoperative tool to detect and localize focal lesions in the pancreas that are causing hyperinsulinism.


Description:

Congenital hyperinsulinism (CHI) is a clinically and genetically heterogeneous disorder that is the most common cause of permanent hypoglycemia in infants and children. More than 50% of the medically-unresponsive patients have focal disease. Which is characterized by a distinct region of Beta-cell hyperplasia in the pancreas, due to a somatic loss of a gene that regulates cell proliferation. Resection of the involved region cures most cases of focal HI. Therefore, preoperative identification and localization of focal HI lesions is useful for diagnostic confirmation and surgical guidance of patients with HI that fail pharmacological therapy and are being considered for surgery. Insulinomas are benign insulin secreting neuroendocrine neoplasms located in the pancreas. They are the most common cause of endogenous hyperinsulinemic hypoglycemia in adults. Approximately 90% are solitary, benign and < 2cm in diameter and therefore represent a challenge to localize. The small size of insulinomas makes detection by conventional imaging techniques such as contrast-enhanced CT (ceCT) and contrast-enhanced MRI challenging. As surgery appears to be the only available treatment option, it remains very critical to localize the tumor to facilitate pancreas preserving surgery. Endoscopic ultrasound is well established in the detection of insulinomas. However, this technique is operator dependent, invasive, and the visualization of the pancreas tail is not always possible. Therefore better imaging techniques to detect these lesions are needed for surgical planning. Though not FDA approved, noninvasive imaging with 18F-fluoro-L-DOPA (FDOPA) is considered an integral part of standards of care management to identify focal lesions in CHI and potentially insulinomas. This is based on the fact that 18F-DOPA is selectively taken up by neuroendocrine cells, and thus, in focal HI, dense collections of endocrine cells can be visualized by an experienced radiologist. This study aims to determine if using combined positron emission tomography and magnetic resonance imaging will better localize the lesions and help the investigators determine which areas of the pancreas are affected, and assist with the surgical plan.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date January 1, 2030
Est. primary completion date January 1, 2030
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: 1. Patients with confirmed hyperinsulinemic hypoglycemia, diagnosed by elevated insulin levels during hypoglycemia and/or response to glucagon stimulation. 2. Subjects who failed pharmacological therapy with diazoxide or octreotide. 3. Subjects with signed informed consent by themselves or their parents or legal guardians. 4. Patient's Endocrinologist has determined that the patient cannot be safely managed with standard medical therapy (failed) and surgery is recommended to prevent future episodes of severe hypoglycemia and preserve brain function. Exclusion Criteria: 1. Any other major illness or condition that in the investigator's judgment will substantially increase the risk associated with the subject's participation in this study. 2. Patient must not have any contraindication to MRI as evaluated by a standardized MRI safety questionnaire. If MRI is contraindicated, and patient meets inclusion criteria and has no other contraindications study will be conducted in PET/CT scanner. 3. Cases in which surgery will not be considered by parents or guardians.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
18F-Fluoro Dopa PET/MRI Imaging
The purpose of this research study is to provide access to an imaging study of the pancreas that uses 6-[18F]-Fluoro-L-3,4,-dihydroxyphenylalanine (18F-DOPA)positron emission tomography (PET) and assess the accuracy of this 18F-DOPA-PET/MRI test on distinguishing what part of the pancreas is affected in patients with Hyperinsulinism.

Locations

Country Name City State
United States Washington University Saint Louis Missouri

Sponsors (2)

Lead Sponsor Collaborator
Washington University School of Medicine St. Louis Children's Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Increase Access to 18F-DOPA PET/MRI (or PET/CT) for patients with HI who failed medical therapy To provide access to 18F-DOPA PET/MRI (or PET/CT) for patients with HI who do not respond to pharmacological therapy and are being considered for pancreatic surgery. We will measure this by totaling the number of scans performed yearly. one year
Secondary Accuracy of 18FDOPA PET/MRI to identify focal forms of hyperinsulinism that may be cured by surgery To identify if data from 18FDOPA PET/MRI imaging can accurately diagnose focal forms of HI when compared to the gold-standard of histopathological findings obtained at surgery in subjects who received a partial or complete pancreatectomy. Currently this type of isotope is not available for diagnosis, of insulinomas. one year
See also
  Status Clinical Trial Phase
Completed NCT00073775 - Epidemiology of Stress and the Metabolic Syndrome N/A
Completed NCT00074451 - Genomewide Search for Loci Underlying Metabolic Syndrome
Completed NCT00005709 - Lipoprotein Metabolism in Hypertensive African-Americans N/A
Completed NCT00005380 - Insulin, Androgen, and Risk in African-American Women N/A
Not yet recruiting NCT05950282 - Fasting Insulin and HOMA-IR by Age, Sex, Race/Ethnicity, BMI, and PCOS Diagnosis
Completed NCT02248272 - Effect of Meal Frequency on Glycemic Control of People at High Risk or Diagnosed With Diabetes N/A
Completed NCT00937079 - Whole Body 111In-exendin-4 Imaging Study in Insulinoma Patients Phase 1
Completed NCT00151684 - Diazoxide-Mediated Insulin Suppression in Hyperinsulinemic Obese Men Phase 2
Completed NCT00004825 - Short Term Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism N/A
Completed NCT00005530 - Diet, Insulin Resistance, and Cardiovascular Risk N/A
Recruiting NCT05662189 - Assessment of Pancreatic Beta Cell Mass and Function by Positron Emission Tomography Imaging in Human Diabetes Mellitus N/A
Recruiting NCT04744896 - Effects Of Combined Cryolipolysis And High Intensity Interval Training On Insulin Resistance And Body Composition In Polycystic Ovarian Patients N/A
Completed NCT05329337 - Link Between the Peripheral Mononuclear Cells' Capacity to Induce Insulin Resistance and Hyperinsulinemia N/A
Not yet recruiting NCT05989347 - Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy Phase 1
Recruiting NCT05543083 - Cognitive-Behavioral Therapy and Exercise Training in Adolescents At-Risk for Type 2 Diabetes N/A
Recruiting NCT05774613 - Effect of Hibiscus Sabdariffa Beverage N/A
Recruiting NCT06363929 - Continuous Glucose Monitoring in Neonatal Hyperinsulinism
Completed NCT03358745 - Impact of Meal Order on Postprandial Cardiometabolic Risk Markers N/A
Not yet recruiting NCT05764200 - Acute Microbial Switch N/A
Completed NCT00005104 - Randomized Study of Decreased Hyperinsulinemia on the Ovulatory Response to Clomiphene Citrate in Women With Polycystic Ovary Syndrome N/A